IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1094 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2384    
    Printed92    
    Emailed1    
    PDF Downloaded153    
    Comments [Add]    

Recommend this journal

 

 RESEARCH PAPER
Year : 1999  |  Volume : 31  |  Issue : 2  |  Page : 120-123

Effects of finasteride and epristeride on steroid 5a-reductase kinetics-A comparative in vitro study



Correspondence Address:
Zu-Yue Sun


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objective: To compare the effect of finasteride with that of epristeride on 5(-reductase kinetics in vitro to explain the increase in serum testosterone level by finasteride but not by epristeride when treated for benign prostatic hyperplasia. Methods: Sprague-Dawley rat liver microsomal crude suspension served as the source of steroid ?(?-reductase. The enzyme, Tris-HCl buffer, [3H] testosterone and epristeride or finasteride were incubated together at 37oC for 20 min. The substrate, [3H] testosterone, and its product, [3H] dihydrotestosterone (DHT) were isolated by thin-layer chromatography. To measure the initial velocity of [3H] DHT (the activity of 5(-reductase), the radioactivity of [3H] DHT, scrapped off thin-layer plate was determined with isotope scintillation counter. The enzyme activity was expressed as (M/min of [3H] DHT. Results: Epristeride was an uncompetitive inhibitor, but finasteride was a competitive one to steroid 5(- reductase and their inhibition constants were 67 ( 19 and 25 ( 3 nM, respectively. Conclusion: The inhibition mechanism of finasteride different from epristeride perhaps was the reason for increase in serum testosterone levels in patients with benign prostatic hyperplasia treated by finasteride.






[PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow